play videoplay video

Video duration 00 minutes 58 seconds 00:58

If you suffer from obesity, a recent study reveals which drugs will help you lose more weight? Munjaro or Ozempic.

The study was conducted by researchers from the US-based research firm Trovita and published in MidArcIffe, and has not yet been peer-reviewed.

The study found that people who were overweight or obese lost more weight and faster with Mongaro compared to the drug Osembek.

Within one year of starting treatment, 42.3% of those who took Tirzepatide, the active ingredient in Mongaro and Zepbound, lost at least 15% of their weight, compared to 19.3% among patients who took semaglutide, the main ingredient in Wegovy and Ozimbek.


Patients who took Mongaro were 76% more likely to lose at least 5% of their body weight, more than twice as likely to lose at least 10%, and more than 3 times more likely to lose at least 15% compared to patients taking Ozymbic.

The researchers used electronic health records and pharmacy dispensing data to analyze the weight loss pathways of 9193,110 patients receiving Mongaro and the same number of patients receiving Uzembek. The average weight of the participant was <> kilograms, and about half of them had type II diabetes.

The study also found that after 3 months of treatment, patients who took Monjaro lost 2.3% more weight on average than those who took Ozymbic. After 6 months, the spread widened to 4.3%, and by 12 months, the Mongaro Group had lost 7.2% more weight on average.

Dr Nick Stacky, author of the study and vice president of Trovita Research, said: "This study could help inform patient care and outcomes today, not months from now.

The researchers found that patients without type II diabetes lost more weight than those with the condition, but the differences in effectiveness between Mongaro and Osembek were similar in both groups.

Difference between Monjaro and Osembek

Mongaro and Osembek are weekly injections that change the way patients eat and lead to decreased appetite by mimicking certain hormones in the gut.

Ozimbek and Wygovi mimic just one hunger-regulating hormone called a glucagon-1-like peptide, also known as GLP-1, which increases feelings of fullness and lowers blood sugar levels.

In contrast, Mongaro and Zibond mimic a glucagon-1 peptide and another hormone in the gut called glucose-dependent insulin polypeptide, or GIP, that is, they mimic two hormones.

The dual approach means that Mongaro and Zibond have an enhanced effect on appetite regulation and blood sugar levels, which some experts say may lead to greater weight loss than drugs that target just glucagon-like peptide.

Source : Al Jazeera + Agencies + Reuters